Skip to main content
. 2022 Feb 4;327(10):980–983. doi: 10.1001/jama.2022.1243

Figure. Fee-for-Service Medicare Beneficiaries With COVID-19 Receiving mAb Therapy by State.

Figure.

mAb indicates monoclonal antibody. Proportion of Medicare beneficiaries with a documented COVID-19 diagnosis or exposure to a confirmed case of COVID-19 receiving mAb therapy between November 2020 and August 2021. Patients hospitalized or deceased within 7 days of COVID-19 diagnosis were excluded.